Abstract alzheimer's disease (aD) is a progressive neurodegenerative disease leading to the irreversible loss of brain neurons and cognitive abilities, and the vicious interplay between oxidative stress (OS) and tauopathy is believed to be one of the major players in aD development. Here, we demonstrated the capability of the small molecule N-(1,3-benzodioxol-5-yl)-2-[5-chloro-2-methoxy(phenylsulfonyl)anilino]acetamide (LX2343) to ameliorate the cognitive dysfunction of aD model rats by inhibiting OS-induced neuronal apoptosis and tauopathy. Streptozotocin (STZ) was used to induce OS in neuronal cells in vitro and in aD model rats that were made by intracerebroventricular injection of STZ (3 mg/kg, bilaterally), and Morris water maze test was used to evaluate the cognitive dysfunction in ICV-STZ rats. Treatment with LX2343 (5-20 μmol/L) significantly attenuated STZ-induced apoptosis in SH-SY5Y cells and mouse primary cortical neurons by alleviating OS and inhibiting the JNK/p38 and pro-apoptotic pathways. LX2343 was able to restore the integrity of mitochondrial function and morphology, increase aTP biosynthesis, and reduce ROS accumulation in the neuronal cells. In addition, LX2343 was found to be a non-ATP competitive GSK-3β inhibitor with IC 50 of 1.84±0.07 μmol/L, and it potently inhibited tau hyperphosphorylation in the neuronal cells. In ICV-STZ rats, administration of LX2343 (7, 21 mg·kg -1 ·d -1
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by memory and cognitive declines, disorientation, and personality changes, and eventually leads to death [1] . Currently, more than 35 million people are suffering from AD, and this figure is projected to grow to 106.8 million people by 2050 [2] . Apart from the slow and progressive degeneration process with synaptic loss leading to a final neuronal death, the accumulation of amyloid β (Aβ) plaques and the formation of neurofibrillary tangles (NFTs) in the brain are accepted as the main hallmarks of AD [3] . For a long time, there has been considerable effort devoted to searching for medications that can be used to treat AD. However, to date, an effective treatment for this disease has not been found because of its complicated pathogenesis, as indicated by the fact that a series of potential anti-AD drugs had favorable therapeutic effects in vitro but failed to work in patients [4] . Therefore, a new strategy is urgently needed for the discovery of anti-AD drugs.
Studies have demonstrated that oxidative imbalance is a manifestation of AD that even precedes Aβ deposition and NFTs formation, and plays a crucial role in neuronal degeneration [5, 6] . Increased oxidative stress (OS) has been implicated in the aging process and is a result of the imbalance between the generation and clearance of reactive oxygen species (ROS). As a main source of ROS, progressive mitochondrial dysfunction may in turn amplify oxidative deficits. The brain is highly vulnerable to oxidative imbalance due to its intensive energy demand, high oxygen consumption, and relative paucity of antioxidants and related enzymes. Thus, it is no wonder that OS-mediated damage is extensively observed in AD. Since mitochondria lie in the center of intrinsic apoptotic events, persistent OS and mitochondrial dysfunction likely lead to further activation of neuronal apoptosis cascades and deficits of cognitive and behavioral functions [7] . Interestingly, evidence has revealed that OS is closely linked to tau pathology, including tau hyperphosphorylation, polymerization and toxicity [7] . Tau protein is associated with microtubule dynamics, which are mainly responsible for maintaining neuronal morphology and functional integrity [8] . Abnormal hyperphosphorylation of tau impairs its capacity for binding to microtubules and maintaining microtubule assembly, resulting in microtubule disorganization, transport defects along axonal microtubules and self-aggregation into NFTs, causing further toxic effects in neuronal cells [9] . In addition, accumulation of hyperphosphorylated tau promotes ROS production, while ROS in turn directly stimulates tau hyperphosphorylation and aggregation. Such a vicious cycle largely propagates the pathogenesis of AD, thereby accelerating the progression of this disease [7] . In our previous work [10] , we reported that the small molecular compound N-(1,3-benzodioxol-5-yl)-2-[5-chloro-2-methoxy(phenylsulfonyl)anilino]acetamide (LX2343, Figure  1A ) was able to alleviate Aβ accumulation by both promoting its clearance and suppressing its production under streptozotocin (STZ)-induced AD pathological conditions and effectively ameliorates cognitive dysfunction in APP/PS1 transgenic mice. Given that oxidative damage and tau hyperphosphorylation are two of the characteristic pathological features induced by STZ in vitro and in vivo [11] , here, we performed the related assays in an attempt to investigate the potential regulation of OS-involved events and tau hyperphosphorylation by LX2343 under STZ-induced pathological conditions. Interestingly, we discovered that LX2343 effectively reversed the STZinduced neuronal apoptosis and tau hyperphosphorylation in vitro and in vivo, and this neuroprotective effect of LX2343 was ascribed to its function in the inhibition of OS and tauopathy. Combined with our previous discovery of the Aβ inhibitory efficacy of this agent [10] , our results demonstrate that LX2343 is a multi-target agent that exhibits a high capability for ameliorating multi-abnormalities of AD pathogenesis, thus strongly supporting the potential of LX2343 in the treatment of AD.
Materials and methods

Materials
All cell culture reagents were purchased from Gibco (Invitrogen, Grand Island, NY, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), streptozotocin (STZ), vitamin E (VE), and lithium chloride were purchased from Sigma-Aldrich (St Louis, MO, USA). SB216763 and PHA-793887 were purchased from Selleck (Houston, TX, USA). LX2343 was purchased from the commercial compound library (SPECS, Zoetermeer, Netherlands).
Cell culture SH-SY5Y cells were grown in a 1:1 mixture of Dulbecco's modified Eagle medium and Ham's F-12 (DMEM/F12) supplemented with 10% fetal bovine serum (FBS) and 100 units/mL of penicillin-streptomycin. Cells were cultured in a humidified incubator with 5% CO 2 at 37 °C.
Primary cortical neuron culture Primary neuronal cultures from embryonic mouse brains (embryonic d 16 to 18) were created according to the approach described in the literature [12] . Briefly, cerebral cortices were separated from the brain, minced into small pieces, digested with D-Hanks buffer (5.4 mmol/L KCl, 0.41 mmol/L KH 2 PO 4 , 138 mmol/L NaCl, 4.5 mmol/L NaHCO 3 , 0.22 mmol/L Na 2 HPO 4 , pH 7.4) containing 0.125% trypsin and 200 U/mL DNase (Sigma-Aldrich, St Louis, MO, USA) and then incubated for 15 min at 37 °C, followed by mechanical dissociation by pipetting in DMEM with 10% FBS. The isolated neurons were seeded at a density of 500 000 cells/mL on poly-D-lysine (Sigma-Aldrich, St Louis, MO, USA)-coated cell culture plates. After 6 h, the medium was replaced by a neurobasal medium supplemented with 2% B27, 0.5 mmol/L L-glutamine, and 50 U/mL penicillin-streptomycin. Cultures were kept in a humidified incubator with 5% CO 2 at 37 °C.
MTT assay
The viability of the cultured cells was determined by assaying the reduction of MTT to formazan. SH-SY5Y or neuronal cells were seeded overnight in 48-well plates at a density of 10 5 cells/well in 100 μL medium. The cells were then incubated with different concentrations of LX2343 (5, 10, or 20 μmol/L) and STZ (0.8 mmol/L for SH-SY5Y cells, 0.4 mmol/L for neuronal cells) for 24 h and washed twice with PBS, followed by the addition of MTT (0.5 mg/mL). After incubation at 37 °C for 4 h, 200 μL DMSO was added to dissolve the formazan crystals, and the absorbance at 490 nm was measured using an M5 spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
FACS assay
SH-SY5Y cells were incubated with STZ (0.8 mmol/L) for 24 h and then collected. Cell apoptosis was measured using an Annexin V-FITC apoptosis detection kit (Beyotime Company, China) following the manufacturer's protocol. The proportion of cell apoptosis was determined by Flow Cytometry (BD Bioscience Company, San Jose, CA, USA).
Intracellular ROS assay
The production of intracellular ROS was measured by fluorescence microscopy (Olympus Company, Tokyo, Japan) using an oxidation-sensitive probe, 20,70-dichlorofluorescein diacetate (DCFH-DA) (Beyotime Company, Haimen, China). After exposing either the SH-SY5Y or the primary neuronal cells to STZ (0.8 mmol/L or 0.4 mmol/L, respectively) with different concentrations of LX2343 (5, 10, or 20 μmol/L) for 8 h, the ROS 
Mitochondrial membrane potential assay
The mitochondrial membrane potential (MMP) was determined using the MMP Kit (Beyotime Company, Haimen, China). The assay involved exposing either SH-SY5Y or neuronal cells to STZ (0.8 or 0.4 mmol/L, respectively) with different concentrations of LX2343 (5, 10, or 20 μmol/L) for 8 h in 12-well plates. The assay details were as described in the manufacturer's protocol.
Mitochondrial function assay
The concentration of ATP was measured using the ATP assay kit (Beyotime Company, Haimen, China GSK-3β enzymatic activity assay GSK-3β inhibition by LX2343 was evaluated by performing an ELISA according to the published approach [13] . Briefly, recombinant human GSK-3β (Invitrogen, Grand Island, NY, USA) was added to the reactions with the substrate-recombinant human TAU-441 (Merck Millipore, Darmstadt, Germany) in a 5:1 ratio. The reaction buffer contained 40 mmol/L HEPES, 5 mmol/L MgCl 2 , 1 mmol/L EDTA, 50 μg/mL of heparin and 100, 30, or 10 μmol/L ATP, and had a pH of 7.2. The reaction mixture was incubated at 37 °C for 1 h. The amount of phosphorylated TAU-441 was measured using a human Tau [pS396] ELISA kit (Invitrogen, Grand Island, NY, USA).
Western blot
The cell-based assays involved exposing either the SH-SY5Y or the primary neuronal cells to STZ (0.8 mmol/L or 0.4 mmol/L, respectively), treating with different concentrations of LX2343 (5, 10, or 20 μmol/L), and then lysing with RIPA buffer (Thermo Scientific, Waltham, MA, USA) containing a protease inhibitor cocktail (Thermo Scientific, Waltham, MA, USA). The protein concentration was determined using a BCA protein assay kit (Thermo Scientific, Waltham, MA, USA). Proteins were mixed with 2× SDS-PAGE sample buffer (25% SDS, 62.5 mmol/L Tris-HCl, pH 6.8, 25% glycerol, 0.5 mol/L DTT, and 0.1% bromophenol blue) and then boiled for 15 min at 99 °C.
For cytochrome c (cyt c) analysis, both cytoplasmic and mitochondrial extracts were collected separately using the Mitochondria/Cytosol Fraction kit (Sangon Biotech, Shanghai, China). The cytoplasmic protein concentration was determined using the BCA protein assay kit (Thermo Scientific, Waltham, MA, USA). The mitochondrial protein concentration was determined using the Non-Interference Protein Assay Kit (Sangon Biotech, Shanghai, China), and mitochondrial proteins were mixed with 5× SDS-PAGE sample buffer (10% SDS, 250 mmol/L Tris-HCl, pH 6.8, 50% glycerol, 0.5 mol/L DTT, and 0.25% bromophenol blue) and then boiled for 15 min at 99 °C.
The brain tissue-based assays involved homogenizing the rat brain tissue with RIPA buffer (Thermo Scientific, Waltham, MA, USA) containing a protease inhibitor cocktail and phosphatase inhibitor cocktails (Thermo Scientific, Waltham, MA, USA) using a hand-held motor. The homogenates were kept on ice for 1 h to ensure that the cells lysed completely. The homogenates were then centrifuged at 20 000×g for 30 min at 4 °C. The supernatant was collected and the protein concentration was determined using the BCA protein assay kit. Equal amounts of lysate (4 mg/mL protein) were mixed with 2× SDS-PAGE sample buffers and then boiled for 15 min at 99 °C. Three individual samples of each of the four groups are shown in Results because only 12 lanes were available in each gel; the other samples were analyzed but are not shown in the figures.
Antibodies against p-JNK, JNK, p-p38, p38, p-c-Jun, c-Jun, p-Erk, Erk, cleaved caspase-3, caspase-3, Bcl-2, Bcl-xl, BAX, p-Bad, Bad, PSD95, Synaptophysin, VAMP2, Tau, P 9 -GSK-3β, p25, p35, CDK5, and GAPDH were obtained from Cell Signaling Technology (Danvers, MA, USA). An antibody against P 216 -GSK-3β was purchased from Santa Cruz (TX, USA). Antibodies against P
396
-Tau, P 199 -Tau, and P 231 -Tau were purchased from Abcam (Cambridge, UK). For Western blot analysis, cell or tissue extracts were separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane filter (GE Healthcare, Madison, WI, USA). After incubation with the corresponding antibodies overnight, the blots were visualized using the Dura detection system (Thermo Scientific, Waltham, MA, USA).
Animal experiments
All animal experiments were performed according to the institutional ethical guidelines on animal care of Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
Forty adult male Sprague Dawley (SD) rats weighing 140-160 g were used in the study. The rats were randomly divided into four groups (ten in each group) and maintained under standard conditions at room temperature (22 °C) with a 12 h light/dark cycle. The animals were purchased from Slac Laboratory Animal Co Ltd (Shanghai, China). The rats in the first group (V) treated with vehicle did not have surgery because previous studies [14] and our results (Supplementary Figure S1A-S1B) both demonstrated that there was no significant difference in the behavior and cognitive function of control rats (without surgery) and that of sham rats (recipients of an ICV injection of vehicle). The rats in the second group (SV) were injected with ICV-STZ (3 mg/kg bilaterally) and vehicle, and the rats in the third (SL) and fourth (SH) groups were injected with ICV-STZ and different doses of LX2343 (7 and 21 mg/kg, respectively). LX2343 was dissolved in 3% DMSO and 5% Tween-80. Before surgery, pre-administration of LX2343 was carried out for 2 weeks. The treatment was maintained for 21 consecutive days after surgery. The brief surgical procedure was performed as follows. Rats were anesthetized with 10% chloral hydrate intraperitoneally and placed on a stereotaxic frame. Holes were drilled in the skull on both sides over the lateral ventricles according to the following coordinates: 0.8 mm posterior to the bregma, 1.5 mm lateral to the saggital suture, and 3.6 mm beneath the surface of the brain. The lesion groups received a bilateral ICV injection of STZ (3 mg/kg, 10 μL/each side). STZ was dissolved in artificial CSF (147 mmol/L NaCl, 2.9 mmol/L KCl, 1.6 mmol/L MgCl 2 , 1.7 mmol/L CaCl 2 , and 2.2 mmol/L dextrose). All microinjections were performed slowly at a speed of 2 μL/min, and the needle remained in position for more than 2 min to prevent reflux along the injection tract.
Morris water maze test
The Morris water maze (MWM) test was carried out as previously described [15] . Briefly, in the training trials, rats were trained to find the invisible submerged white platform in a circular pool (120 cm in diameter, 50 cm deep) filled with inktinted water using a variety of visual cues located on the pool wall. Three trials were performed each day for 5 consecutive days (the first 4 d were trials for the latency assay and the fifth day for the crossing-times assay). In each trial, rats were given 60 s to find the invisible platform. The animals were allowed to stay at the platform for 10 s if they found the platform within the given time. However, if the animals failed to find the platform within the given time, they were manually placed on the platform and left there for 10 s. On the last day, after the training trials, a probe trial was performed by removing the platform. The animals were allowed to swim for 60 s in search of the platform. All data were collected for animal performance analysis. For data analysis, the pool was divided into four equal quadrants, formed by imaging lines that intersected in the center of the pool at right angles, called north, south, east, and west.
Immunohistochemistry
Immunohistochemistry assays were performed to detect the expression of P 396 -Tau protein.
The tissue was embedded in paraffin and sectioned with a microtome to create sections 5-μm thick. The slides were dewaxed and washed with PBS several times and preincubated in 1% horse serum for 45 min at 37 °C. Thereafter, the slides were incubated overnight at 4 °C with the primary antibody anti-P 396 -Tau polyclonal (dilution 1:400). Then, the sections were incubated with fluorescent secondary detection reagents (1:500, Invitrogen, Grand Island, NY, USA). The slides were observed under a fluorescence microscope.
TUNEL assay
Cell death in animal brain tissue was detected using the in situ cell death detection kit, POD (Roche, Rotkreuz, Switzerland), according to the manufacturer's protocol. Briefly, the assay was based on the detection of DNA fragmentation resulting from apoptosis signaling cascades by labeling the DNA strand breaks using terminal deoxynucleotidyl transferase [16] .
Statistical analysis
All data were obtained from three independent experiments in which experiments were performed in triplicate, at least. All data are presented as the mean±SEM, and the exact values of the mean±SEM are presented in Supplementary Table S1 . The significant difference between multiple treatments and the control was analyzed using a one-way ANOVA with Dunnett's post-test. The STZ treatment (SV) was used as the positive control to evaluate the ameliorative effects of compounds on AD pathologies. A P value of less than 0.05 was considered to be statistically significant.
Results
LX2343 protected neurons from apoptosis by ameliorating OS and mitochondrial dysfunction LX2343 protected neurons from apoptosis
Given that STZ has been widely used to induce OS-mediated cell apoptosis both in vitro and in vivo [11, 17] , we investigated the potential neuronal protective effects of LX2343 in SH-SY5Y and primary neuronal cells by using STZ as an inducer for cell death. The effect of STZ on neuron viability was first evaluated using the MTT assay. The results indicated that 0.4-3.2 mmol/L STZ showed a dose-dependent inhibitory activity on cell viability ( Figure 1B, 1C) and, therefore, the STZ dose was set at 0.8 mmol/L for SH-SY5Y and 0.4 mmol/L for primary neuronal cells in all subsequent assays. As demonstrated in Figure 1D and 1E, STZ treatment induced an 18.11%±1.15% and 27.82%±0.82% decrease in cell viability for SH-SY5Y and primary neuronal cells, respectively, while co-incubation with LX2343 effectively antagonized the effects of STZ. In addition, quantitative evaluation of apoptosis in SH-SY5Y cells using Annexin V-FITC staining further demonstrated the capability of LX2343 to prevent STZ-induced apoptosis ( Figure 1F) . Compared with the controls, the apoptosis rate of the SH-SY5Y cells was increased to 21.88%±0.91% when the cells were stimulated with STZ, and the apoptosis rate was decreased to 14.57%±0.66% after the cells were co-incubated with 20 μmol/L LX2343. These data indicated that treating SH-SY5Y and primary neuronal cells with LX2343 could reduce cell death and increase cell viability.
Next, given that STZ-induced OS stimulation may disturb synapse integrity [18] , we examined whether LX2343 could also regulate the expression of synapse-associated proteins in pri-mary neuronal cells. For this purpose, the protein levels of the postsynaptic density protein 95 (PSD95), synaptophysin, and vesicle-associated membrane protein 2 (VAMP2), which are crucial for neurotransmission and synaptic plasticity [19] , were detected by Western blot. As expected, compared with the controls, the expression of PSD95, synaptophysin, and VAMP2 was decreased to 66%±3.7%, 46%±4.7%, and 50%±4.1%, respectively, after exposure to STZ for 8 h. However, LX2343 dose-dependently abolished the STZ-induced reduction in the expression of these proteins, thereby implying the potential protection of this compound against synapse integrity ( Figure  1G, 1H) .
Taken together, all these results indicated that LX2343 exhibited neuronal protective effects.
LX2343 alleviated STZ-induced OS and ameliorated mitochondrial dysfunction
Because ROS and mitochondrial dysfunction are two of the primary pathological features of AD [20] and are widely implicated in STZ-induced cell death [21] , we next examined whether LX2343 affected ROS accumulation in cells with antioxidant VE as a positive control [22] . As expected, ROS generation was greatly increased after STZ incubation in both SH-SY5Y (162.45%±0.043%) (Figure 2A, 2B ) and primary neuronal cells (126.35%±3.50%) ( Figure 2C, 2D) , whereas 100 μmol/L VE inhibited such STZ-induced effects. Furthermore, LX2343 treatment efficiently inhibited the accumulation of intracellular ROS in both SH-SY5Y (Figure 2A, 2B ) and primary neuronal cells ( Figure 2C, 2D) . Moreover, the combination of LX2343 with VE exhibited a synergistic action in the prevention of STZ-induced apoptosis (Supplementary Figure S2) . These results indicated that the neuroprotective ability of LX2343 involves an inhibitory effect on ROS accumulation.
According to previous reports, mitochondria are major producers of ROS, playing a fundamental role in the maintenance of internal homeostasis, and alterations in mitochondrial membrane integrity are one of the crucial events in ROS generation and early apoptosis [23] . Therefore, the effect of LX2343 Figure 2E, 2F) , implying that LX2343 could help to maintain mitochondrial membrane integrity. In addition, the results of the assay of mitochondrial ultrastructure morphology in SH-SY5Y cells also demonstrated that the cells that received the STZ treatment had swollen mitochondria with decreased matrix electron density and disorganized and fragmented cristae, while LX2343 incubation effectively ameliorated these STZ-induced abnormalities of mitochondria ( Figure 2G ). Moreover, given that mitochondrial dysfunction may promote ROS production due to an impairment in normal regulation of the redox state and energy metabolism, the level of intracellular ATP was measured to evaluate mitochondrial function. As expected, the ATP content of the SH-SY5Y and primary neuronal cells decreased to 79.87%±2.048% and 80.25%±1.53%, respectively, when treated with STZ, but cotreatment of the SH-SY5Y and primary neuronal cells with LX2343 effectively attenuated the reduction of ATP in a dosedependent manner ( Figure 2H, 2I) .
Therefore, all the data suggested that LX2343 decreased the STZ-induced OS and ameliorated mitochondrial dysfunction.
LX2343 inhibited JNK/p38 signaling
Since intracellular ROS activate the mitogen-activated protein kinase (MAPK) pathway in the mediation of STZ-induced cell death [24, 25] , we next investigated whether LX2343 has a regulatory effect on the MAPK pathway. The results demonstrated that incubating SH-SY5Y and primary neuronal cells with STZ for 4 h induced an ~2.5-fold increase in JNK and p38 phosphorylation compared with the controls (Figure 3A) , whereas LX2343 treatment antagonized the STZ-induced increase in phosphorylated JNK, c-Jun, and p38 in both SH-SY5Y ( Figure 3B, 3C ) and primary neuronal cells ( Figure 3D , 3E) but had no effects on ERK ( Figure 3A and 3F) or p53 (Figure 3F ) in SH-SY5Y cells. These data thus indicated that the neuronal protective effect of LX2343 involves JNK/p38 pathway inhibition. 
LX2343 regulated apoptosis-relevant proteins
The Bcl-2 family consists of both anti-and pro-apoptotic members that share four conserved regions known as Bcl-2 homology domains (BH1-4). The relative amounts of antiand pro-apoptotic proteins determine the fate of cells, whether to remain viable or to enter into apoptosis [26] . Dysregulation of Bcl-2 family members damages mitochondrial outer membrane permeability and promotes efflux of cytochrome c and other death-inducing factors from mitochondria to initiate the apoptotic caspase cascade [27] . Based on these facts, we investigated the regulation of Bcl-2 family proteins by LX2343 in both SH-SY5Y and primary neuronal cells using Western blot in an attempt to explore the mechanism underlying the protective effects of LX2343 against STZ-induced neurotoxicity. The results indicated that STZ treatment decreased the expression levels of the anti-apoptotic proteins Bcl-2 and Bcl-xl, increased the expression levels of the pro-apoptotic protein Bax, and reduced the phosphorylation of Bad, which self-inactivates Bad activity, while LX2343 incubation inhibited the apoptotic process by up-regulating anti-apoptotic proteins and downregulating pro-apoptotic proteins ( Figure 4A-4D) . Similarly, LX2343 ameliorated the STZ-induced increase in cleaved caspase-3 ( Figure 4A-4D ). In addition, the regulation of cyt c distribution by LX2343 was also confirmed with cytosolic and mitochondrial fractions prepared using SH-SY5Y cells; here, LX2343 treatment markedly abolished STZ-induced cytochrome c release ( Figure 4E, 4F ).
LX2343 suppressed tauopathy involving GSK-3β enzymatic activity inhibition LX2343 restrained tau phosphorylation
Considering the association of OS with tauopathy, we examined the potential of LX2343 to suppress tau hyperphosphorylation at multiple sites, including serine 396 and 199, and threonine 231 [28] . As expected, the results indicated that LX2343 efficiently attenuated the STZ-induced elevation of tau phosphorylation in both SH-SY5Y ( Figure 5A , 5B) and primary neuronal cells ( Figure 5C, 5D ).
LX2343 was a non-ATP competitive GSK-3β inhibitor
It is reported that phosphorylation of tau is regulated by a series of kinases and phosphatases [28] . Glycogen synthase kinase-3β (GSK-3β) and cyclin-dependent kinase 5 (CDK5) are two proline-directed tau kinases that phosphorylate tau at a large number of serine and threonine residues, thus playing an important role in the tau pathology of AD [29, 30] . GSK-3β is activated through phosphorylation of Tyr 216 and inhibited by phosphorylation of Ser 9 [29] . CDK5 alone is an inactive cata- lytic subunit that can be activated by p35 or p25 (the cleaved product of p35) [30] . Next, we detected the phosphorylation level of GSK-3β in both SH-SY5Y and primary neuronal cells using lithium chloride (LiCl) as a positive control [31] . The results demonstrated that both LX2343 and LiCl increased the phosphorylation at Ser 9 and decreased the phosphorylation at Tyr 216 of GSK-3β in both SH-SY5Y ( Figure 5E , 5F) and primary neuronal cells ( Figure 5G, 5H) , indicating an alleviation of GSK-3β enzymatic activity [29] . Furthermore, the in vitro GSK-3β enzymatic activity assay results further verified the inhibition of the GSK-3β enzyme by LX2343 with an IC 50 of 1.84±0.07 μmol/L ( Figure  5I , SB216763 is a positive control [32] ). Furthermore, to test whether competition exists between LX2343 and ATP, we investigated the effects of different concentrations of ATP on the inhibitory activity of the compound against the enzyme. The results demonstrated that inhibition of GSK-3β by LX2343 was virtually unaffected even at a high concentration of ATP ( Figure 5J ), which suggested that LX2343 is a non-ATP competitive inhibitor of GSK-3β. Notably, LX2343 had no effect on the protein level of either CDK5 or p35/p25 ( Figure 6A-6D) , and the results of the in vitro assay also suggested that LX2343 had no effect on CDK5/p25 kinase enzyme activity ( Figure 6E , PHA-793887 is a positive control [33] ). Taken together, LX2343 suppressed tauopathy by inhibiting GSK-3β enzymatic activity.
LX2343 ameliorated learning and memory impairments in ICV-STZ rats ICV injection of rats with a sub-diabetogenic dose of STV has been shown to be closely linked to the sporadic dementia of Alzheimer's disease [34] , which is characterized by cognitive impairment [35] , OS [35] , impaired glucose metabolism [36] , and hyperphosphorylated tau [37] . Given the pathological features of ICV-STZ rats and the efficiency of LX2343 in both protecting neuronal cells and attenuating tau pathology, we performed the MWM assay to examine the potential of LX2343 in the amelioration of memory impairment in ICV-STZ rats. To evaluate the ameliorative effects of LX2343 in AD pathologies, we chose SV as the positive control mimicking the AD pathological conditions. The results indicated that the latency time for the rats to find the hidden platform after undergoing the four-day training trials was reduced in all groups, but STZlesioned (SV) rats presented a longer latency time than the vehicle group (V), which suggested that the poorer learning performance was due to the ICV-STZ infusion administered to these rats ( Figure 7B ). Notably, LX2343 treatment improved the learning performance in the SL and SH groups when compared to the SV group. The distances swum (path lengths) by the rats while trying to find the platform on the fourth day are shown in Figure 7A . Similar to the latency time results, the path length for the rats in the SV group was longer than that for the V group, but the path length could be shortened in both the SL and SH group with LX2343 administration. According to the results of the probe trial, the rats in the SV group failed to remember the location of the platform: these rats spent less time in the target quadrant and crossed the target quadrant less frequently than the rats in the V group ( Figure 7C, 7D ). However, all those deficits were improved with the administration of LX2343, which suggests that LX2343 ameliorated learning and memory deficits in ICV-STZ rats.
LX2343 inhibited neuronal apoptosis in ICV-STZ rats
Positive cells with apoptotic nuclei showed a green-fluorescent stain after TUNEL staining. The results demonstrated that only a few TUNEL-positive cells were present in the hippocampus and cerebral cortex of normal control rats, whereas a greater number of TUNEL-positive cells were found in STZ-treated rats ( Figure 8A, 8B) . Notably, administration of LX2343 attenuated neuron apoptosis in STZ-treated rats (Figure 8A, 8B) .
Western blot results also demonstrated that phosphorylation levels of JNK, c-Jun, and p38 were stimulated in both the cerebral cortex ( Figure 8C, 8D ) and hippocampus ( Figure  8E , 8F) of ICV-STZ rats compared with those of control rats. Furthermore, administration of LX2343 effectively attenuated such increases in ICV-STZ rats ( Figure 8C-8F) .
In addition, the in vivo regulation of the Bcl-2 superfamily and caspase-3 by LX2343 administration was also confirmed in ICV-STZ rats. The results demonstrated lower expression of Bcl-2/Bcl-xl and Bad phosphorylation and higher expression of Bax and the cleaved product of caspase-3 in the SV group compared with those in the V group in both the cerebral cortex ( Figure 9A, 9B ) and the hippocampus ( Figure 9C,  9D ) of ICV-STZ rats. LX2343 administration antagonized the shifts towards the pro-apoptotic process in both the cerebral cortex and the hippocampus of ICV-STZ rats (Figure 9A-9D) . Taken together, these results indicated that LX2343 effectively inhibited neuronal apoptosis in the cerebral cortex and hippocampus of ICV-STZ rats through the inhibition of the JNK/ P38 and pro-apoptotic pathways.
Moreover, we confirmed that the protein levels of PSD95, synaptophysin, and VAMP2 were lower in the STZ-injured rat group compared to the normal control group (Figure 9E-9H) . Notably, administration of LX2343 efficiently ameliorated the STZ-induced suppression of PSD95, synaptophysin and VAMP2 protein levels in both the cerebral cortex ( Figure 9E , 9F) and the hippocampus ( Figure 9G, 9H ) of ICV-STZ injected rats. These results support the conclusion that LX2343 alleviated synaptic plasticity damage in STZ-ICV rats.
LX2343 attenuated tau hyperphosphorylation and GSK-3β phosphoryl ation in ICV-STZ rats To investigate the regulation of tau pathology by LX2343 in ICV-STZ rats, phosphorylation of tau was first evaluated by immunohistochemistry. The results ( Figure 10A , 10B) noticeably indicated immuno-reactive tau phosphorylation (white arrow) in the brains of ICV-STZ rats with higher fluorescence intensity compared to that in normal rats, and the administration of LX2343 to the rats in the SL and SH groups repressed the STZ-induced increase in tau phosphorylation. Next, a Western blot assay of homogenates of the cerebral cortex (Figure 10C, 10D ) and the hippocampus ( Figure 10E, 10F ) was also applied to evaluate the alleviation of tau phosphorylation by LX2343 in ICV-STZ rats. As expected, LX2343 administration in both the SL and SH groups apparently antagonized the STZ-induced increase in tau phosphorylation at multiple sites, including serine 396, serine 199, and threonine 231. In addi- Figure  10G , 10H) and hippocampal ( Figure 10I , 10J) homogenates also indicated that LX2343 administration in both the SL and SH groups stimulated the inactive form of GSK-3β (P-S9) but suppressed the active form of GSK-3β (P-Y216) in ICV-STZ rats.
Discussion
AD is one of the most devastating diseases leading to an irreversible progressive cognitive impairment and is a serious threat to the elderly. However, the discovery of effective anti-AD drugs is full of challenges because of the complexity of AD pathogenesis. In our previous study [10] , we determined that small molecule LX2343 effectively ameliorated the cognitive deficits in APP/PS1 mice, targeting both Aβ production and clearance. Here, we also demonstrated the capability of LX2343 to treat ICV-STZ model rats through both neuronal protection and tau inhibition. Therefore, the triple effects of LX2343 on neuroprotection, Aβ inhibition, and tau modulation indicate the potential of this multi-target compound in the treatment of AD.
OS is a pivotal cellular response to the damage caused by tau toxicity, and the vicious interaction between these two causative events promotes AD progression [38] . Studies have identified OS as an early marker of tauopathy since OS and mitochondrial dysfunction are detected prior to tau hyperphosphorylation and NFT accumulation in tau P301S transgenic mice, which show tau hyperphosphorylation and tangle formation in 3 months [39] . On the one hand, OS amplifies tauinduced neurotoxicity by induction of apoptosis and dysregulation of cell energy metabolism and promotes tau hyperphosphorylation and aggregation [38] . On the other hand, tauopathy induces OS [40] . Some OS markers are notably increased in tauopathy, such as malondialdehyde and 4-hydroxynonenal [41] [42] [43] . The activation of antioxidant defenses is also observed in tauopathy [44, 45] . Such a positive feed-forward loop of OS and tauopathy greatly promotes AD progression and makes its pathogenesis more intricate. www.chinaphar.com Guo XD et al
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In view of the close link between OS and tauopathy, many antioxidants have recently been discovered that protect against tauopathy in different AD models. For example, vitamin E decreased ROS production and tau phosphorylation [22, 46] and chronic administration of coenzyme Q10 to tau P301S mice alleviated ROS accumulation and tau hyperphosphorylation, thus improving behavioral deficits in the transgenic mice [40] . Although the results obtained using animal studies have suggested that antioxidants are potential therapeutic agents for the treatment of AD and tauopathy-relevant diseases, the translation of these inspiring results obtained in animal models into clinical use has not yet led to significant advances [38] . Therefore, new strategies are needed to design effective agents against OS or tauopathy to break the deadlock. Here, we discovered that LX2343 was able to ameliorate both OS and tauopathy at the same time; LX2343 substantially reduced ROS accumulation similar to an antioxidant and restored mitochondrial function through stabilizing the mitochondrial membrane potential, maintaining mitochondrial morphological integrity, and increasing ATP biosynthesis. In addition, LX2343 also suppressed hyperphosphorylation of tau by inhibition of GSK-3β. Thus, the dual effect of LX2343 has emphasized its potential for breaking the cycle of OS and tauopathy.
GSK-3β as an isoform of GSK-3 can phosphorylate tau at several sites, and its dysregulation is responsible for tau hyperphosphorylation. In addition to the regulation of tau, GSK-3β also plays a pivotal role in other cellular functions [47, 48] . It is reported that GSK-3β regulates apoptotic pathways directly or indirectly. It directly triggers the mitochondrial apoptosis cascade by promoting Bax translocation to mitochondria [49] and indirectly leads to canonical Wnt pathway-mediated apoptosis through phosphorylation of β-catenin [50] . Here, we also investigated the regulatory effects of LX2343-mediated GSK-3β inhibition against apoptosis. Interestingly, Western blot results demonstrated a decrease in Bax translocation to mitochondria with LX2343 treatment (Supplementary Figure S3A) , but no effects on the Wnt pathway were determined as LX2343 did not alleviate the phosphorylation of β-catenin (Supplementary Figure S3B ). These results indicated that the direct inhibition of GSK-3β by LX2343 might contribute, at least partly, to the efficacy of LX2343 in neuroprotection. Collectively, our data showed that small molecule LX2343 effectively improved cognitive dysfunction in ICV-STZ AD model rats by suppression of both OS-induced neuronal apoptosis and tauopathy. The underlying mechanisms have been intensively investigated. As shown in Figure 11 , LX2343 rescued neuronal cells from apoptosis by maintaining the integrity of mitochondrial function and morphology, alleviating OS and the JNK/p38 pathway and regulating anti-and pro-apoptotic proteins. In addition, LX2343 also potently inhibited tau hyperphosphorylation by functioning as a non-ATP competitive inhibitor of GSK-3β. Combined with our previous finding [10] , our current work has largely enriched our knowledge of the pharmacological efficacy of LX2343 in the treatment of AD.
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. all values were presented as the mean±SEM (n=10 per group). GaPDH was used as the loading control in Western blot assays. Data were obtained from three independent experiments.
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